NewAmsterdam Pharma (NASDAQ:NAMS) Trading Down 6.4% – Time to Sell?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)’s share price traded down 6.4% during mid-day trading on Monday . The company traded as low as $33.22 and last traded at $32.94. 280,801 shares changed hands during mid-day trading, a decline of 56% from the average session volume of 635,724 shares. The stock had previously closed at $35.20.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on NAMS shares. Needham & Company LLC increased their target price on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. The Goldman Sachs Group boosted their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the company a “neutral” rating in a research report on Tuesday, December 2nd. Citigroup upped their price target on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, October 17th. HC Wainwright assumed coverage on shares of NewAmsterdam Pharma in a research note on Monday, October 20th. They issued a “buy” rating and a $52.00 price objective for the company. Finally, Stifel Nicolaus boosted their target price on shares of NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a report on Tuesday, December 16th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, NewAmsterdam Pharma presently has an average rating of “Moderate Buy” and a consensus price target of $45.90.

NewAmsterdam Pharma Trading Down 4.9%

The company’s fifty day simple moving average is $36.96 and its 200 day simple moving average is $29.58. The stock has a market capitalization of $3.80 billion, a P/E ratio of -16.33 and a beta of 0.07.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.38) by ($0.03). The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. Equities research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Insiders Place Their Bets

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock in a transaction that occurred on Friday, December 26th. The shares were sold at an average price of $35.30, for a total transaction of $1,548,681.60. Following the completion of the sale, the chief accounting officer directly owned 15,000 shares in the company, valued at $529,500. The trade was a 74.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders have sold 145,000 shares of company stock valued at $5,196,741 over the last quarter. Company insiders own 20.84% of the company’s stock.

Institutional Investors Weigh In On NewAmsterdam Pharma

A number of large investors have recently added to or reduced their stakes in NAMS. PTM Wealth Management LLC bought a new position in NewAmsterdam Pharma during the 2nd quarter valued at approximately $256,000. Knights of Columbus Asset Advisors LLC bought a new stake in shares of NewAmsterdam Pharma during the 2nd quarter valued at $595,000. Franklin Resources Inc. grew its holdings in NewAmsterdam Pharma by 30.6% in the second quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock worth $6,053,000 after purchasing an additional 78,300 shares during the period. Frazier Life Sciences Management L.P. grew its stake in shares of NewAmsterdam Pharma by 3.0% in the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after buying an additional 490,656 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of NewAmsterdam Pharma by 47.2% in the second quarter. JPMorgan Chase & Co. now owns 1,458,897 shares of the company’s stock worth $26,421,000 after acquiring an additional 467,579 shares during the last quarter. Hedge funds and other institutional investors own 89.89% of the company’s stock.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.